Not enough data
Eliza Slawther's articles predominantly focus on legal policy regulation and government announcements within the healthcare and pharmaceutical industry. Her coverage revolves around institutions such as EMA (European Medicines Agency) and FDA (Food and Drug Administration), with a specific emphasis on drug development, AI regulation, and their impacts.
Given her emphasis on government announcements and regulatory developments in the pharma industry, she would likely be interested in pitches from experts who can provide analysis or commentary about new regulations, policies, or major decisions made by these agencies. Sources well-versed in the workings of EMA, FDA, drug approval processes or AI applications in healthcare are likely to attract her attention.
As Eliza's geographic focus is not specified but given the nature of her coverage related to European agencies like EMA along with global entities like FDA suggests an international outlook for potential stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jul By, Eliza Slawther
MS drugs Kesimpta and Ocrevus are to remain subsidized in Australia while a rapid review for a long-term pricing solution takes place. Health minister Mark Butler said US pricing policies were one factor putting pressure on Australia and “reverberating right through the world.”
A proposed extension to supplementary protection certificates under the EU Biotech Act has proven divisive. Regardless of its outcome, the EU will need to demonstrate that it is a place where innovative biotech investment can generate returns, says senior lawyer Grant Castle.
By: Jul By, Eliza Slawther
The UK medicines regulator improved its compliance with statutory turnaround times for national drug licensing applications from 8% to 98% last year, while targets on scientific advice also improved markedly.
By: Jul By, Eliza Slawther
Cancer drugs could benefit from an update to the value set used by England's health technology assessment institute, NICE, but other drugs for chronic conditions could be deemed less cost-effective under the proposed changes.
By: Jul By, Eliza Slawther
The European Medicines Agency recommended against the pan-EU approval of Proveca/Cessatech's KemSu for pain in children, Zevra's ultra-rare disease drug, Meplyffa, and Advenchen's cancer drug, Quezzaqar.
By: Jul By, Eliza Slawther
Lynavoy, GSK's orphan drug for primary biliary cholangitis, is among 12 drugs set for pan-EU approval following a positive recommendation from the European Medicines Agency this month.
By: Eliza Slawther
Roche’s refillable ocular implant Susvimo has been recommended for pan-EU marketing approval by the European Medicines Agency, three years after the company withdrew its initial marketing authorization filing in the EU.
By: Eliza Slawther, Jul By
Janssen's patent for the dosing regimen behind its schizophrenia drug Invega Sustenna has been upheld by Canada's Supreme Court, blocking Pharmascience's generic competitor from the market. However, a bid from Janssen to broaden dosing patent rules in general was denied.
By: Jul By, Eliza Slawther
Cytokinetics' Myqorzo, a once-daily pill for obstructive hypertrophic cardiomyopathy, is set to reach English patients faster than usual due to “closer working” between the UK drug regulator and England's health technology assessment institute.
By: Eliza Slawther, Jul By
Cytokinetics' Andrew Callos says biotechs entering Europe must plan for lower-than-expected prices from the start, and discusses lessons learnt from the US biotech's EU rollout of its heart drug Myqorzo.
